FDA Approves Ionis' ZANVASTRO as First Disease-Modifying Treatment for Alexander Disease — Ionis Pharmaceuticals, Inc.

Event summary

FDA approved ZANVASTRO (zilganersen) for Alexander disease (AxD) in pediatric and adult patients on September 3, 2026.
ZANVASTRO is the first and only disease-modifying treatment for AxD, an ultra-rare neurological disorder.
The approval was based on positive results from a pivotal study showing statistically significant stabilization of gait speed.
Ionis entered a license agreement with Recordati for exclusive rights to develop and commercialize zilganersen outside the U.S.
The FDA granted Ionis a Rare Pediatric Disease Priority Review Voucher (PRV) with the approval.

The big picture

This approval marks a significant milestone for Ionis, as it represents the company's first independent launch from its neurology pipeline. The success of ZANVASTRO underscores the potential of RNA-targeted technology in addressing serious neurological diseases with limited treatment options. The strategic partnership with Recordati positions Ionis to capitalize on global market opportunities, further solidifying its leadership in the rare disease space.

What we're watching

Commercialization Strategy: How Ionis will execute the launch of ZANVASTRO in the U.S. and prepare for regulatory submissions in Europe and Japan in 2027.
Market Expansion: Whether the partnership with Recordati will successfully expand ZANVASTRO's reach in international markets.
Pipeline Progress: The pace at which Ionis advances its other neurology pipeline candidates, following this milestone.